Posts Tagged ‘obesity treatment’

When people take a GLP-1 like semaglutide, osteoarthritis often improves. It makes sense. Excess body weight puts a strain on joints, especially the knee. And randomized controlled studies document the clinical benefits. New research confirms what clinical scientists have long suspected. Treating obesity can do more than just relieve the strain of excess weight on […]

It would be hard to find a sharper contrast than the one displayed yesterday in the report of fourth quarter 2025 business results for Eli Lilly and Novo Nordisk. Lilly is enjoying the best of times. Novo is suffering the worst. “Eli Lilly’s GLP-1 growth is only getting started,” says CNBC, “as Novo Nordisk braces […]

At the same time a daily tablet of an advanced obesity medicine is capturing much attention, two new monthly obesity medicines are advancing. The first, Maritide, is something we’ve been following for a while now. Amgen provided an update yesterday with their latest quarterly briefing on business results. The second is the fruit of a […]

We are in the midst of what used to be known as diet and weight loss season. And now the Super Bowl is coming up. Instead of diet ads this year, our video feeds are full of ads for telehealth and GLP-1s. Some of them are annoying. But when Serena Williams comes on screen to […]

Yesterday, Roche announced topline results from a phase two study of a new injectable dual agonist medicine for obesity. The drug, CT-388, delivered a reduction in body weight of 22.5% after 48 weeks at the highest dose tested (24 mg). Placebo-subtracted weight loss was 18.3% and at 48 weeks, patients taking the drug were still […]

Reporting for the Washington Post, Daniel Gilbert tells us “the next frontier in weight-loss drugs is one-time gene therapy.” Setting aside his misuse of the “weight-loss” misnomer, should we take him seriously? How much can we expect from gene-based therapies for obesity? Scientifically Substantial The body of peer-reviewed evidence for genetic therapies in obesity is […]

As we move through the first month of real-world utilization, Wegovy tablets are showing unexpectedly strong uptake for obesity – getting a head start on the anticipated arrival of Lilly’s orforglipron. Early utilization data suggest Wegovy in an oral form might be carving out meaningful space in obesity, defying initial skepticism. The Skepticism When enthusiasm […]

A steady stream of headlines makes it obvious. The incomprehensibility of a chronic disease like obesity is overwhelming. The New York Times tells us it’s a hard truth about obesity medicines: “You’ll probably need them forever.” The wellness industry is peddling dubious strategies for an “off-ramp” from GLP-1 therapies with inflated claims about “sustained remission.” […]

U.S. spending on healthcare hit a new record in 2024 – $5.3 trillion. That is a seven percent jump from the prior year, maintaining a longstanding pattern of health spends rising faster than spending on everything else in this economy. But how can it be that, despite all this spending, the burden of chronic diseases […]

It’s a neat trick. The newest kid on the block in obesity care is part of the oldest in the diabetes neighborhood. It is the Obesity Association of the American Diabetes Association. And yesterday, the OA of the ADA showed that it can play well with others by publishing landmark Standards of Care for obesity […]